Answering The Call For Antidotes
Bad publicity about bleeding events spells headaches for drug developers, but also an opportunity for companies that can come up with antidotes to reverse anticoagulation effects.
You may also be interested in...
Boehringer, Perosphere Anticoagulant Antidotes Advance At AHA
At a time when demand for anticoagulant antidotes is high, the 2013 AHA meeting featured the first human data for two new reversal agents from Boehringer Ingelheim and Perosphere. Perosphere will be pursuing “breakthrough therapy” status with FDA for its intravenous small molecule candidate PER977.
Eliquis Poised To Wake Up U.S. Oral Anticoagulant Market
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.
The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.